<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23897">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02795676</url>
  </required_header>
  <id_info>
    <org_study_id>PB-102-F20</org_study_id>
    <nct_id>NCT02795676</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function</brief_title>
  <acronym>BALANCE</acronym>
  <official_title>A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protalix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protalix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double blind, active control study of PRX-102 in Fabry disease
      patients with impaired renal function. Patients treated for at least 1 year with agalsidase
      beta and on a stable dose for at least 6 months will be screened and then randomized to
      continue treatment with either agalsidase beta at the same dose or to treatment with 1 mg/kg
      of PRX-102. The identity of the enzyme will be blinded to the patient and the investigator.
      Patients will receive intravenous infusions every two weeks. Patients will be randomized in
      a 2:1 ratio of PRX-102 to agalsidase beta. Randomization will be stratified by urinary
      protein to creatinine ratio (UPCR) of &lt; or ≥ 1 g/g by spot urine sample.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>eGFR Slope</measure>
    <time_frame>Every month for 2 years</time_frame>
    <description>Annualized change in eGFR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Mass Index (g/m2) by MRI</measure>
    <time_frame>Every 12 months for 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>Every 2 weeks for 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Lyso-Gb3</measure>
    <time_frame>Every 3 months for 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Gb3</measure>
    <time_frame>Every 3 months for 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine Lyso-GB3</measure>
    <time_frame>Every 6 weeks for 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein/creatinine ratio</measure>
    <time_frame>Every 4 months for 24 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Area under the curve</measure>
    <time_frame>Every 6 months for 2 years</time_frame>
    <description>PRX-102 pharmacokinetics to evaluate comparative AUCs</description>
  </other_outcome>
  <other_outcome>
    <measure>Anti-drug antibodies</measure>
    <time_frame>Every 4 months for 2 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>PRX-102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRX-102 infusion every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Agalsidase beta</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Agalsidase beta infusion every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PRX-102</intervention_name>
    <description>PRX-102 1 mg/kg every 2 weeks</description>
    <arm_group_label>PRX-102</arm_group_label>
    <other_name>Pegunigalsidase alfa</other_name>
    <other_name>Recombinant human alpha galactosidase-A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Agalsidase beta</intervention_name>
    <description>Agalsidase beta 1 mg/kg every 2 weeks</description>
    <arm_group_label>Agalsidase beta</arm_group_label>
    <other_name>Fabrazyme</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic adult Fabry disease patients, age 18-60 years

               1. Plasma and/or leucocyte alpha galactosidase activity (by activity assay) less
                  than 30% mean normal levels

               2. One or more of the described characteristic features of Fabry disease:

             i. neuropathic pain, ii. cornea verticillata, iii. clustered angiokeratoma

          -  Screening eGFR by CKD-EPI equation 40 to 90 mL/min/1.73 m2

          -  Linear negative slope of eGFR based on at least 3 serum creatinine values over
             approximately 1 year (range of 9 to 18 months, including the value obtained at the
             screening visit) of ≥ 2 mL/min/1.73 m2/year

          -  Treatment with a dose of 1 mg/kg agalsidase beta per infusion every 2 weeks for at
             least one year and at least 80% of 13 (10.4) mg/kg total dose over the last 6 months.

        Exclusion Criteria:

          -  History of anaphylaxis or Type 1 hypersensitivity reaction to agalsidase beta

          -  History of renal dialysis or transplantation

          -  History of acute kidney injury in the 12 months prior to screening, including
             specific kidney diseases (e.g., acute interstitial nephritis, acute glomerular and
             vasculitic renal diseases); non-specific conditions (e.g, ischemia, toxic injury); as
             well as extrarenal pathology (e.g., prerenal azotemia, and acute postrenal
             obstructive nephropathy)

          -  Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB)
             therapy initiated or dose changed in the 4 weeks prior to screening

          -  Urine protein to creatinine ratio (UPCR) &gt; 0.5 g/g and not treated with an ACE
             inhibitor or AR

          -  Cardiovascular event (myocardial infarction, unstable angina) in the 6 month period
             before randomization

          -  Congestive heart failure NYHA Class IV

          -  Cerebrovascular event (stroke, transient ischemic attack) in the 6 month period
             before randomization

          -  Known history of hypersensitivity to Gadolinium contrast agent

          -  Presence of any medical, emotional, behavioral or psychological condition that, in
             the judgment of the Investigator and/or Medical Director, would interfere with the
             patient's compliance with the requirements of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raul Chertkoff, MD</last_name>
    <role>Study Director</role>
    <affiliation>Protalix Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mali Szlaifer, MS</last_name>
    <phone>+972(0)4-902-8100</phone>
    <phone_ext>180</phone_ext>
    <email>malis@protalix.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UAB Medicine</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric L Wallace, MD</last_name>
      <phone>205-975-9676</phone>
      <email>ericlwallace@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Eric L Wallace, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Wilcox, MD</last_name>
      <phone>404-727-5624</phone>
      <email>william.wilcox@emory.edu</email>
    </contact>
    <investigator>
      <last_name>William Wilcox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hosptials and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myrl Holida, MD</last_name>
      <phone>319-356-2007</phone>
      <email>myrl-holida@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Myrl Holida, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infusion Associates</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49525</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kahn Nedd, MD</last_name>
      <phone>616-954-0600</phone>
      <email>khannedd@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Kahn Nedd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Lau, MD</last_name>
      <phone>212-263-8344</phone>
    </contact>
    <investigator>
      <last_name>Heather Lau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Hopkin, MD</last_name>
      <phone>513-803-1846</phone>
      <email>rob.hopkin@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Robert Hopkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerard Vockley, MD, PhD</last_name>
      <phone>412-692-7746</phone>
      <email>gerard.vockley@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Gerard Vockley, Md, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Metabolic Disease, Baylor Healthcare</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raphael Schiffmann, MD, MHSc</last_name>
      <phone>214-820-4533</phone>
      <email>raphael.schiffmann@baylorhealth.edu</email>
    </contact>
    <investigator>
      <last_name>Raphael Schiffmann, MD, MHSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eccles Primary Children's Outpatient Services Building</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Longo, MD, PhD</last_name>
      <phone>801-581-7609</phone>
      <email>nicola.longo@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Nicola Longo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>O+O Alpan LLC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ozlem Goker-Alpan, MD</last_name>
      <phone>571-308-1900</phone>
    </contact>
    <contact_backup>
      <last_name>Tabitha Taber</last_name>
      <phone>571-308-1906</phone>
    </contact_backup>
    <investigator>
      <last_name>Ozlem Goker-Alpan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Nicholls, MD</last_name>
      <phone>+61393427000</phone>
      <email>kathy.nicholls@mh.org.au</email>
    </contact>
    <investigator>
      <last_name>Kathleen Nicholls, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francois Eyskens, MD</last_name>
      <phone>+32 3 821 31 82</phone>
      <email>francois.eyskens@uza.be</email>
    </contact>
    <investigator>
      <last_name>Francois Eyskens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Capital Health</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael L West, MD</last_name>
      <phone>+9024734023</phone>
      <email>mlwest@dal.ca</email>
    </contact>
    <investigator>
      <last_name>Michael L West, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ales Linhart, MD</last_name>
      <phone>+420224962605</phone>
      <email>ales.linhart@lf1.cuni.cz</email>
    </contact>
    <investigator>
      <last_name>Ales Linhart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Wuerzburg</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Wanner, MD</last_name>
      <phone>+49931020139030</phone>
      <email>wanner_c@klinik.uni-wuerzburg.de</email>
    </contact>
    <investigator>
      <last_name>Christoph Wanner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M J Molnar, MD</last_name>
      <email>molnarmj@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria J Molnar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amseterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>CEM Hollak, MD</last_name>
      <phone>+31205666071</phone>
      <email>c.e.hollak@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>CEM Hollak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helse Bergen HF Haukeland Universitetssykehus</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Camilla Tøndel, MD</last_name>
      <phone>+4755973859</phone>
      <email>camilla.tondel@helse-bergen.no</email>
    </contact>
    <investigator>
      <last_name>Camilla Tøndel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology and Clinical Research Private Institute</name>
      <address>
        <city>Asuncion</city>
        <country>Paraguay</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Derlis Emilio Gonzalez Rodriguez, MD</last_name>
      <phone>595-21-423603</phone>
      <email>gderlis@conexion.com.py</email>
    </contact>
    <investigator>
      <last_name>Derlis Emilio Gonzales Rodriguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Dia Quiron Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <zip>50012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatriz Escuder</last_name>
      <phone>+34 976 765 500</phone>
      <email>bea.escuderazuara@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pilar Giraldo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department and Laboratory of Pediatric Metabolic Disorders</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>F Ezgu, MD</last_name>
      <phone>+903122141000</phone>
      <phone_ext>6107</phone_ext>
      <email>fezgu@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>F Ezgu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ege Universty Medical Faculty</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kalkan Sema, MD</last_name>
      <phone>+905057797312</phone>
      <email>semakalkan@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Kalkan Sema, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Deegan, MD</last_name>
      <phone>+441223245151</phone>
      <email>patrick.deegan@addenbrookes.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Patrick Deegan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Lachmann, MD</last_name>
      <phone>+442078298778</phone>
      <email>robin.lachmann@uclh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Robin Lachmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derralynn Hughes, MD</last_name>
      <phone>44 207 472 6588</phone>
      <email>rmgvdah@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Derralynn Hughes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Jovanovic, Md</last_name>
      <phone>+441612064365</phone>
      <email>ana.jovanovic@srft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Ana Jovanovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Paraguay</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 9, 2017</lastchanged_date>
  <firstreceived_date>June 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glomerular filtration rate</keyword>
  <keyword>Proteinuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
